Stay updated on Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial page.

Latest updates to the Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial page
- Check2 days agoChange DetectedRevision metadata updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedLocations now include Massachusetts; HHS Vulnerability Disclosure and Massachusetts Locations sections were removed.SummaryDifference0.2%

- Check45 days agoChange DetectedRevision: v3.3.2 is now shown, replacing the previous v3.3.1. No other study content or functionality appears to be affected.SummaryDifference0.1%

- Check52 days agoChange DetectedMinor wording updates to the Publications section indicate that items are automatically filled from PubMed, and revision numbers have been updated to v3.3.1 and v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check60 days agoChange DetectedRemoved the banner that informed users about a lapse in government funding and NIH operating status. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check74 days agoChange DetectedEnrollment updated to 90 participants with a Primary Completion date of 2018-10-11 and a Study Completion date of 2023-09-05.SummaryDifference0.5%

Stay in the know with updates to Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial page.